NHS England South - PGD Page

Patient Group Directions (PGDs) are written instructions for the supply or administration of medicines to groups of patients who may not be individually identified before presentation for treatment. NHS PGDs must only be used as part of a commissioned NHS service.

PGD’s are now being posted on the NHS England South website link to page

October 2023

Three new PGDs have been authorised for Hep A, Hep B and Hep A&B, please follow link above

Hepatitis A Vaccine PGD v5.00 (AVAXIM®, AVAXIM® Junior, Havrix® Monodose®, Havrix® Junior Monodose®, VAQTA® Adult, or VAQTA® Paediatric) – valid from 31st October 2023

For the administration of Hepatitis A virus (inactivated) vaccine (adsorbed), to individuals considered at high risk of exposure to hepatitis A or post exposure to hepatitis A virus in accordance with national recommendations. See Green Book ( Chapter 17 ).

Changes from v4.00 include:

Hepatitis B Vaccine PGD v5.00 (Engerix B®, HBVAXPRO®, PreHevbri® or HEPLISAV B®) – valid from 31st October 2023

For the administration of Hepatitis B recombinant DNA (rDNA) vaccine (adsorbed) to individuals considered at increased risk of exposure to hepatitis B virus, at increased risk of complications of hepatitis B disease, or post potential exposure to hepatitis B virus. See Green Book ( Chapter 18 ).

Changes from v4.00 include:

Hepatitis A+B Vaccine PGD v4.00 (Ambirix®, Twinrix® Adult, and Twinrix® Paediatric) – valid from 31st October 2023

For the administration of combined hepatitis A virus (inactivated) and hepatitis B recombinant DNA (rDNA) (Hep A and B) vaccine (adsorbed) to individuals requiring protection against hepatitis A and hepatitis B virus in accordance with national recommendations.. See Green Book ( Chapter 17 and Chapter 18 ).

Changes from v3.00 include:

August 2023

Four new PGDs have been authorised for a range of registered healthcare professionals to use .

Two new PGDs have been authorised for a range of registered healthcare professionals to use.

Before staff use these, your organisation should ensure that those members of staff have signed section 7, and that this has been counter-signed by an authorising manager.

Note that PGDs can only be used as legal authorisation for administration or supply of prescription-only medicines by a limited number of registered health professions. Other staff that cannot prescribe will require a patient specific direction ( guidance here).

Inactivated influenza vaccine PGD V11.00 - valid from 1 September 2022

for the administration of inactivated influenza vaccine to individuals in accordance with the national influenza immunisation programme

Changes from V10.00:

Live attenuated influenza vaccine nasal spray suspension (LAIV) PGD V11.00 (Fluenz® Tetra) - valid from 1 September 2022

for the supply and administration, or supply only, of live attenuated influenza vaccine (LAIV) nasal spray suspension (Fluenz® Tetra) to children and adolescents from 2 years to under 18 years of age in accordance with the national flu immunisation programme.

Changes from V10.00:

 

One new PGD has been authorised for a range of registered healthcare professionals to use. 20 August 2021

  1. Diphtheria, tetanus, pertussis, polio, Haemophilus influenzae and hepatitis B vaccine (DTaP/IPV/Hib/HepB) PGD V03.00

for the administration of diphtheria, tetanus, pertussis, polio, Haemophilus influenzae and hepatitis B vaccine to individuals from 6 weeks (routinely 8 weeks) to under 10 years of age in accordance with the national immunisation programme

Changes from V2.00:

HPV vaccine PGD V04.00

for the administration of human papillomavirus vaccine (HPV) to individuals from 12 years of age or from school year 8 in accordance with the national immunisation programme

Changes from V03.00:

Three new PGDs have been authorised for a range of registered healthcare professionals to use:

  1. MenACWY Risk Groups PGD V03.00 – valid from 1 March 2021

For the administration of meningococcal group A, C, W, and Y vaccine (MenACWY) to individuals with an underlying medical condition which puts them at increased risk from Neisseria meningitidis.

Updates:

  1. MenB Risk Groups PGD V03.00 – valid from 1 March 2021

For the administration of meningococcal group B vaccine (MenB) to individuals, from 2 years of age, with an underlying medical condition which puts them at increased risk from Neisseria meningitidis group B.

Updates:

  1. MenB PGD V05.00 – valid from 1 March 2021

For the administration of meningococcal group B vaccine (MenB) to individuals from 8 weeks of age eligible for the national routine immunisation programme and to individuals for the prevention of secondary cases of meningococcal group B disease.

Updates:

 

 

 

5202 views